DRG Epidemiology's coverage of neuromyelitis optica syndrome disorder comprises epidemiological estimates of key patient populations across the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom and Japan). We report both the incidence and prevalence of neuromyelitis optica syndrome disorder for each country, as well as annualized case counts projected to the national population.
DRG Epidemiology's neuromyelitis optica syndrome disorder forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of neuromyelitis optica syndrome disorder over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts 2 neuromyelitis optica syndrome disorder patient populations, as follows:
- Diagnosed prevalent cases
- Diagnosed incident cases
- Neuromyelitis Optica Spectrum Disorder (NMOSD) - Epidemiology - Mature Markets
- Key Findings
- Diagnosed Prevalence Estimates of Neuromyelitis Optica Syndrome Disorder per 100,000 People of All Ages in 2020 and 2030
- Relative Sizes of the Contributing Factors to the Trend in Diagnosed Prevalent Cases of Neuromyelitis Optica Syndrome Disorder over the Next Ten Years
- Epidemiology Data
- Diagnosed Prevalent Cases
- Diagnosed Incident Cases
- Reference Materials
- Literature Review
- Studies Included in the Analysis of NMOSD
- Studies Excluded from the Analysis of NMOSD
- Risk/Protective Factors
- Risk/Protective Factors for NMOSD
- Literature Review
Author(s): Mike Hughes, M.Sc., Ph.D.; Sunali D. Goonesekera, S.M.
Mike Hughes, M.Sc., Ph.D., is the director of the Epidemiology department at DRG, part of Clarivate. He joined DRG in 2006 and has many years’ experience in the mathematical modeling of healthcare service delivery, cardiovascular and cancer epidemiology, biostatistics, meta-analysis, and systematic reviewing. He has been principal author on many published articles in leading international journals in the areas of risk modeling in intensive care and cardiovascular medicine. He also helped develop national guidelines on behalf of NICE and the American College of Chest Physicians for the treatment of atrial fibrillation, stroke, and hypertension. He is particularly interested in modeling patient flows in cancer and methods for forecasting disease burden in noncommunicable epidemiology. Dr. Hughes received his Ph.D. in risk modeling in intensive care in 2003 from City University, London, and his Ph.D. in statistical causation and foundations of probability theory from the University of Nottingham.
Sunali Goonesekera, S.M., is a senior epidemiologist at DRG, part of Clarivate. Prior to joining DRG, Ms. Goonesekera conducted epidemiological research on racial/ethnic disparities in metabolic diseases at the New England Research Institute and lead-authored two manuscripts. She has contributed to multiple publications in peer-reviewed journals in epidemiology and the biological sciences. She holds a master’s degree in epidemiology from the Harvard School of Public Health and a B.A. in biology (Honors) from Dartmouth College.